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Saturated Free Fatty Acids Induce Cholangiocyte Lipoapoptosis
Sathish Kumar Natarajan1, Sally A. Ingham1, Ashley M. Mohr1, Cody J. Wehrkamp1, 
Anuttoma Ray1, Sohini Roy1, Sophie C. Cazanave2, Mary Anne Phillippi1, and Justin L. 
Mott1
1Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, 
Omaha, NE
2Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, 
Richmond, VA
Abstract
Recent studies have identified a cholestatic variant of nonalcoholic fatty liver disease (NAFLD) 
with portal inflammation and ductular reaction. Based on reports of biliary damage, as well as 
increased circulating free fatty acids (FFAs) in NAFLD, we hypothesized the involvement of 
cholangiocyte lipoapoptosis as a mechanism of cellular injury. Here, we demonstrate that the 
saturated FFAs palmitate and stearate induced robust and rapid cell death in cholangiocytes. 
Palmitate and stearate induced cholangiocyte lipoapoptosis in a concentration-dependent manner 
in multiple cholangiocyte-derived cell lines. The mechanism of lipoapoptosis relied on the 
activation of caspase 3/7 activity. There was also a significant up-regulation of the proapoptotic 
BH3-containing protein, PUMA. In addition, palmitate-induced cholangiocyte lipoapoptosis 
involved a time-dependent increase in the nuclear localization of forkhead family of transcription 
factor 3 (FoxO3). We show evidence for posttranslational modification of FoxO3, including early 
(6 hours) deacetylation and dephosphorylation that coincide with localization of FoxO3 in the 
nuclear compartment. By 16 hours, nuclear FoxO3 is both phosphorylated and acetylated. 
Knockdown studies confirmed that FoxO3 and its downstream target, PUMA, were critical for 
palmitate- and stearate-induced cholangiocyte lipoapoptosis. Interestingly, cultured cholangiocyte-
derived cells did not accumulate appreciable amounts of neutral lipid upon FFA treatment.
Conclusion—Our data show that the saturated FFAs palmitate and stearate induced 
cholangiocyte lipoapoptosis by way of caspase activation, nuclear translocation of FoxO3, and 
increased proapoptotic PUMA expression. These results suggest that cholangiocyte injury may 
occur through lipoapoptosis in NAFLD and nonalcoholic steatohepatitis patients.
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic 
syndrome.1 NAFLD is a spectrum of liver diseases including simple steatosis, nonalcoholic 
steatohepatitis (NASH), advanced hepatic fibrosis, liver cirrhosis, and hepatocellular 
carcinoma.1 NAFLD is the most common liver disease in Western countries and it is highly 
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associated with obesity, diabetes, dyslipidemia, and hypertension.1 Recently, a cholestatic 
presentation of NAFLD with ductular inflammation, bile duct loss and swelling, and bile 
duct proliferation was reported.2 They also showed that bridging fibrosis or cirrhosis was 
more common in patients with biliary injury.2 This suggests the involvement of biliary 
epithelial cell injury as a possible contributor to the severity of NAFLD or NASH.2,3 Bile 
duct epithelial cell expansion, termed the ductular reaction, is a response to injury and has 
been observed in NAFLD.3
NAFLD patients have elevated concentrations of circulating saturated free fatty acids 
(FFAs). FFA-induced hepatocyte lipoapoptosis is a recognized hallmark of NAFLD and 
includes the activation of p38-mitogen activated protein kinase (p38-MAPK), extracellular 
signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).4 These stress-activated 
kinases have been well known to translocate into the nucleus upon activation and can 
phosphorylate several transcription factors including forkhead family transcription factors 
(FoxO) to regulate gene expression.5 Further, FoxO1 has been shown to be phosphorylated 
by p38 and ERK but not by JNK.5 Phosphorylation of FoxO3, at residue Ser7 by p38, has 
been shown before to promote its nuclear localization and apoptosis in response to 
doxorubicin treatment.6 FoxO3 nuclear translocation increases the expression of 
proapoptotic proteins such as p53-up-regulated modulator of apoptosis (PUMA), Bim, p27, 
and TNF-related apoptosis inducing ligand (TRAIL).7,8 Additionally, FoxO3 has been 
confirmed to have direct transcriptional activity on the PUMA promoter and induces the 
expression of PUMA protein.8 It has been well established that hepatocyte lipoapoptosis is 
dependent on the activation of JNK but the involvement of p38-MAPK and ERK has been 
ruled out.4,9 In the present study we tested the activation of all three stress-dependent 
kinases and their role in cholangiocyte lipoapoptosis.
While hepatocyte lipoapoptosis due to FFAs has been established and implicated in the 
pathogenesis of NAFLD or NASH,4,9 the occurrence of cholangiocyte lipoapoptosis due to 
FFAs has not been thoroughly tested. The present study explores cholangiocyte 
lipoapoptosis using cholangiocyte cell culture models. The data are consistent with saturated 
FFA-induced cholangiocyte lipoapoptosis by way of activation of FoxO3 and up-regulation 
of the proapoptotic BH3-containing protein PUMA.
Materials and Methods
Materials
Palmitic acid (#P5585), stearic acid (#S4751), oleic acid (#O1008), and fatty acid-free 
bovine serum albumin (BSA; #A3803) were obtained from Sigma-Aldrich. The pan-caspase 
inhibitor Z-VAD-fmk and ERK inhibitor FR180204 were from Santa Cruz Biotechnology 
and the JNK inhibitor SP600125 was from Calbiochem. Magnetic protein G beads were 
purchased from New England Bio Labs.
Antibodies
Rabbit antisera against phospho-FoxO3 (Thr32) (#9464), acetylated-lysine (#9441), FoxO3 
(#2497), FoxO1 (#2880), phospho-p38-MAPK (#9211), MAPK (#9212), phospho-ERK1/2 
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(#9101), ERK1/2, phospho-JNK (#9251), JNK (#9252), and p83-MAPK inhibitor 
SB204580 were from Cell Signaling. Rabbit antiserum against PUMA (#ab54288) was from 
Abcam. Goat anti-Lamin B (#sc-6216) and rabbit anti-actin (#sc-1615) were purchased from 
Santa Cruz Biotechnology. Peroxidase-conjugated secondary antibodies were obtained from 
Jackson ImmunoResearch Laboratories.
Cell Lines and Treatment
H69, a human immortalized cholangiocyte cell line and KMCH, Mz-ChA-1, and HuCCT-1, 
human cholangiocarcinoma cell lines were grown as described.11 BDEneu cells were a kind 
gift from Dr. Alphonse Sirica (Virginia Common-wealth University) and were grown as 
described.12 Cells were treated with the indicated concentrations of FFAs (400-800 μM) 
dissolved in isopropanol and added to media containing 1% fatty acid-free BSA for 24 
hours. Vehicle treatment was isopropanol with a final concentration of <1% in the medium.
Measurement of Apoptosis
Percent apoptosis was quantified by characteristic nuclear morphology and visualized by 
treatment with the fluorescent DNA-binding dye, DAPI (4′, 6-diamidine-2′-phenylindole 
dihydrochloride) as described before.9 Briefly, cells were stained with 5 μg/mL of DAPI for 
20-30 minutes at 37°C. Apoptotic nuclei (condensed, fragmented) were counted and 
presented as a percent of total nuclei. At least 100 cells were counted per well and 
experiments were performed in triplicate. Caspase 3/7 activity was measured by enzymatic 
fluorophore release (Apo-One) according to the manufacturer's instructions (Promega) with 
experiments performed in quadruplicate.
Oil Red O Staining
Intracellular lipid droplets were stained using oil red O dye. Cells were treated with 600 μM 
of the indicated FFAs for 24 hours. Cells were washed with phosphate-buffered saline (PBS) 
and fixed with 10% buffered formalin for 10 minutes. Oil red O (2 mg/mL) staining solution 
was added for 15 minutes and washed with water. Cells were mounted using Fluoromount G 
(Electron Microscopy Services). Images were obtained by Olympus 1X71 fluorescent 
microscopy using the rhodamine channel.
Nuclear Isolation, Immunoblot, and Immunofluorescence
Nuclear extracts were prepared as described.13 Cell lysates containing 30 μg of protein were 
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Proteins were transferred to a nitrocellulose membrane and visualized by immunoblotting. 
Mz-ChA-1 cells were labeled with anti-FoxO3 antibody and visualized by Alexafluor 488 
secondary staining.
Lentiviral shRNA Transduction
Short hairpin RNA (shRNA) silencing lentiviral pLKO.1-puro vector targeting FoxO3 and 
PUMA were obtained from Sigma. FoxO3 shRNA#1 and #2 targets the nucleotide 
sequences 2185-2205 and 1626-1648 of FoxO3 mRNA (NM_001455.1), respectively. 
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PUMA shRNA targets the nucleotide sequence 783-805 of PUMA mRNA (NM_014417.2). 
Stable transfections were carried out as described.14
Statistics
Statistical analysis was performed using one-way analysis of variance (ANOVA) with 
Bonferroni posthoc correction, unless indicated otherwise.
Results
FFAs Induced Cholangiocyte Lipoapoptosis
Biochemical characteristics of apoptosis include nuclear morphology changes and activation 
of the caspase cascade. We tested the effect of 400, 600, and 800 μM FFAs on cholangiocyte 
lipoapoptosis. These concentrations were chosen based on circulating levels of total FFAs 
found in NAFLD or NASH patients15 and previous studies.4,9,14 The saturated FFAs 
palmitate (PA) and stearate (SA) induced cholangiocytes to undergo lipoapoptosis in a 
concentration-dependent manner (Fig. 1). Both PA and SA resulted in 25%-60% apoptosis 
in H69 cells (Fig. 1A). The monounsaturated fatty acid, oleate (OA), showed no apoptosis at 
400 μM and 600 μM. OA at 800 μM induced minimal apoptosis in H69 cells compared with 
800 μM of PA- or SA-treated cells. To confirm the apoptotic nuclear changes, we tested the 
activation of caspase 3/7 in FFA-treated cells. PA and SA treatment of cholangiocytes 
resulted in significantly increased caspase 3/7 activity in a concentration-dependent manner. 
Indeed, 600 μM and 800 μM PA resulted in 4- and 6-fold increased caspase 3/7 activity in 
H69 cells, whereas 600 μM and 800 μM SA resulted in 5- and 8-fold increased caspase 3/7 
activity, respectively (Fig. 1A). H69 cells, upon OA treatment, again showed a significant 
increase in caspase activity only at 800 μM OA (Fig. 1A). FFA-induced cholangiocyte 
lipoapoptosis was then tested in additional cholangiocyte-derived cell lines. PA induced an 
increase in the number of apoptotic nuclei in KMCH cells at 600 μM and 800 μM, whereas 
SA induced increased lipoapoptosis starting from 400 μM to 800 μM. Increased caspase 
activity was observed with increasing concentrations of both PA and SA in KMCH cells 
(Fig. 1B). Treatment of KMCH cells with OA did not induce apoptosis (Fig. 1B). Both Mz-
ChA-1 and HuCCT cell lines showed similar FFA-induced apoptosis with increasing 
concentrations of PA and SA, but not with OA (Fig. 1C,D). Together, these results suggest 
that saturated FFAs SA and PA induced cholangiocyte lipoapoptosis.
Caspase-Dependent Cholangiocyte Lipoapoptosis
We next examined whether inhibition of caspases using a cell permeable, pan-caspase 
inhibitor Z-VAD-fmk would prevent FFA-induced cell death. Addition of Z-VAD-fmk (50 
μM) to PA- or SA-treated cells resulted in a significant reduction (although not complete 
elimination) of apoptotic nuclei in H69, KMCH, Mz-ChA-1, and HuCCT cells (Fig. 2A-D). 
In parallel, addition of Z-VAD-fmk to PA- or SA-treated cells resulted in complete 
prevention of caspase 3/7 activity induced by PA and SA treatments (Fig. 2A-D).
To check the generality of cholangiocyte lipoapoptosis across species, we tested BDEneu 
cells, an immortalized tumorigenic rat cholangiocyte which has constitutive overexpression 
of the rat neu/her2 oncogene.12 BDEneu cells treated with vehicle showed 2.39 ± 6 0.8% 
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apoptotic nuclei and 600 μM PA resulted in significantly increased levels of apoptotic nuclei 
to 35 ± 2.2% (Fig. 2E). Treatment with Z-VAD-fmk plus PA significantly decreased the 
percentage of apoptotic nuclei to 16 ± 0.7. In addition, BDEneu cells showed an increase in 
caspase 3/7 activity with 600 μM of PA which was blocked by Z-VAD-fmk (Fig. 2E).
FFAs Induced p38-MAPK, ERK1/2, and JNK Activation
Activation of MAPKs in patients with NAFLD has been reported.16 Here we tested whether 
activation of MAPKs was involved in cholangiocyte lipoapoptosis. Indeed, PA treatment 
resulted in activation of p38-MAPK, ERK, and JNK by way of phosphorylation. Increased 
levels of phospho-p38-MAPK were apparent after 1 hour of PA and remained elevated until 
after 24 hours of PA treatment (Fig. 3A). KMCH cells have some constitutively 
phosphorylated ERK, as seen in vehicle-treated cells, and 2 hours of PA treatment resulted 
in further activation of ERK. The increase in phospho-ERK levels with PA was time-
dependent with peak activation time between 4-8 hours (Fig. 3A). Similarly, JNK is also 
activated by phosphorylation after 1 hour of PA treatment as compared to vehicle-treated 
KMCH cells. Phospho-JNK levels stayed elevated up to 16 hours of PA treatment, with 
peak activation observed at 8 hours of PA (Fig. 3A). PA-induced activation of p38-MAPK, 
ERK, and JNK was also evident in another cholangiocyte, Mz-ChA-1 cells. Here, PA-
treated cells showed activation of p38-MAPK and ERK after 1.5 hours of treatment as 
compared with vehicle-treated cells. Both phospho-p38-MAPK and phospho-ERK levels 
stayed elevated until after 6 hours of PA-treatment and returned to control levels after 8 
hours of PA treatment (Fig. 3B). Phospho-JNK levels were also increased after 1.5 hours of 
PA treatment and stayed elevated until after 3 hours in PA-treated Mz-ChA-1 cells (Fig. 
3B). While all three MAPKs were detectable, total levels of each varied between cell lines 
(Fig. 3C).
We next tested whether inhibition of MAP kinases using small molecule inhibitors would 
prevent PA-induced cholangiocyte lipoapoptosis. First, treatment with SB204580 (20 μM), 
p38 inhibitor showed partial inhibition of PA-induced caspase activation in KMCH, Mz-
ChA-1, HuCCT, and BDEneu cells but not in H69 cells (Fig. 3D). Treatment with 
FR180204 (30 μM), an ATP-binding pocket selective inhibitor of ERK1/2, also partially 
prevented PA-induced caspase activation in Mz-ChA-1, HuCCT, and BDEneu cells. 
FR180204 (30 μM) did not protect against PA-induced caspase activity in H69 and KMCH 
cells (Fig. 3E). SP600125, an inhibitor of JNK, did not alter cholangiocyte lipoapoptosis 
caused by PA in KMCH cells (Fig. 3F) or Mz-ChA-1 cells (Fig. 3G). These results suggest 
that FFAs induced activation of stress kinases p38-MAPK, ERK, and JNK and that 
inhibition of p38-MAPK and ERK altered cholangiocyte lipoapoptosis but inhibition of JNK 
did not alter cholangiocyte lipoapoptosis.
Palmitate Induced FoxO3 Nuclear Localization
We next tested whether FoxO transcription factors (FoxO1 and FoxO3) were involved in 
palmitate-induced cholangiocyte lipoapoptosis. Nuclear extracts were isolated to analyze 
FoxO levels in KMCH cells treated with 800 μM of PA. Increased FoxO3 was observed in 
the nucleus after 3 hours of PA as compared with vehicle-treated cells and nuclear FoxO3 
levels stayed elevated until after 24 hours. Lamin B was used as a loading control (Fig. 4A). 
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Nuclear levels of FoxO3 were also increased in H69 and Mz-ChA-1 cells treated with PA 
for 16 hours (Fig. 4B). FoxO1 expression in the nuclear extracts was high in H69 cells. 
However, FoxO1 levels were not altered with PA treatment in either H69 or Mz-ChA-1 cells 
(Fig. 4B). The levels of total FoxO3 in all the cholangiocytes were comparable (Fig. 3C). To 
check whether nuclear levels of FoxO3 were similar in both SA- and PA-treated cells, 
KMCH, H69, and HuCCT cells were treated with 800 μM PA or SA for 16 hours and 
nuclear extracts were prepared. Both PA and SA treatment resulted in similar increases in 
the nuclear levels of FoxO3 as compared with lamin B (Fig. 4C). Immunofluorescent 
analysis for FoxO3 in Mz-ChA-1 cells demonstrated clear nuclear localization after 16 hours 
of PA treatment as compared to the cytosolic staining observed in vehicle-treated cells (Fig. 
4D). Quantitation of nuclear FoxO3 levels showed a 7-fold increase after 16 hours of PA 
treatment relative to vehicle-treated cells (Fig. 4E). To test posttranslational modifications, 
FoxO3 was immunoprecipitated from nuclear extracts and probed using an anti-acetyl-lysine 
antibody. We observed a dramatic decrease in levels of acetylated FoxO3 6 hours after 
treatment (Fig. 4F). At the same time, FoxO3 was also observed to be unphosphorylated 
(Fig. 4F). At a later timepoint, PA treatment of HuCCT and H69 cells resulted in an increase 
in the nuclear levels of acetylated FoxO3 and phosphorylated FoxO3 (Fig. 4G). These 
results suggest that FoxO3 was deacetylated and dephosphorylated at early timepoints, when 
it first translocated to the nucleus, and at the later timepoints FoxO3 is modified by way of 
acetylation and phosphorylation.
FoxO3 Is Critical for Cholangiocyte Lipoapoptosis
FoxO3 shRNA transduction resulted in complete knockdown in H69 (Fig. 5A) and partial 
knockdown in KMCH cells (Fig. 5B). Control shRNA and FoxO3 shRNA-treated cells were 
then challenged with 800 μM of PA or SA for cholangiocyte lipoapoptosis. H69 cells 
transduced with FoxO3 shRNA showed dramatic protection against PA- or SA-induced 
apoptosis, measured by apoptotic nuclei or caspase 3/7 activity as compared with control 
shRNA-treated cells (Fig. 5C). Similarly, KMCH cells transduced with FoxO3 shRNA 
showed significant protection against PA- or SA-induced cholangiocyte lipoapoptosis as 
compared to control shRNA treated cells (Fig. 5D). Together, these results confirm that 
FoxO3 is critical for FFA-induced cholangiocyte lipoapotosis.
Palmitate Increases PUMA Protein Expression in Cholangiocytes
PUMA is a downstream target of FoxO3,8 thus we assessed the expression of PUMA 
protein in KMCH cells at various timepoints after treatment with 800 μM PA. PA-treated 
KMCH cells showed elevated levels of PUMA after 2 hours as compared to vehicle-treated 
cells and increased PUMA levels were sustained even after 48 hours (Fig. 6A). Similar to 
KMCH cells, the levels of PUMA were also found to be increased by both SA and PA 
treatment in H69, Mz-ChA-1, and HuCCT cells (Fig. 6B). To further validate the 
significance of PUMA in cholangiocyte lipoapoptosis, we transduced control or PUMA 
shRNA in H69 and HuCCT cells and confirmed the knockdown of PUMA protein 
expression (Fig. 6C,D). PUMA knockdown resulted in significant protection against 800 μM 
PA or SA treatment (Fig. 6C,D). Thus, the FoxO3 downstream target, PUMA is also critical 
in FFA-induced cholangiocyte lipoapoptosis.
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Cholangiocytes Did Not Develop Steatosis With FFA Treatment
Treatment of hepatocytes with FFAs was previously shown to increase lipid storage as 
triglycerides in cytoplasmic lipid droplets.4 We tested cholangiocytes such as H69, Mz-
ChA-1, KMCH, and hepatoma cells, Huh7 for lipid droplet formation after treatment with 
600 μM PA, SA, or OA by staining with oil red O dye. H69 cells showed a background of 
minimal lipid droplet staining and this did not increase with PA or SA treatment, whereas 
OA-treated cells showed a slight increase in lipid droplet formation (Fig. 7). Mz-ChA-1 and 
KMCH cells did not show accumulation of lipid droplets with 600 μM of PA, SA, or OA 
after 24 hours. In contrast to cholangiocytes, Huh7 hepatoma cells showed a dramatic 
increase in the accumulation of lipid droplets with all of the FFAs. These results suggest that 
cholangiocytes do not develop steatosis, in contrast to hepatocytes.
Discussion
Circulating saturated FFAs are reported to be elevated in patients with metabolic syndrome 
as well as in patients with NAFLD or NASH.15 The principal finding of this study is that 
FFAs can induce biliary epithelial cell lipoapoptosis. Our data suggest four important 
findings in biliary cell damage induced by FFAs, termed cholangiocyte lipoapoptosis: 1) 
FFAs induced caspase activation and cholangiocyte apoptosis; 2) cholangiocyte 
lipoapoptosis was associated with the activation of FoxO3, a transcription factor known to 
induce apoptosis; 3) cholangiocyte lipoapoptosis appears to involve the activation of 
PUMA, a proapoptotic BH3-containing protein; and 4) unlike hepatocytes, cholangiocytes 
did not accumulate lipid droplets. The schematic representation of FFA-induced 
cholangiocyte lipoapoptosis is shown in Fig. 8. These results will be discussed below.
Are cholangiocyte cell culture models a clinically relevant model to study biliary epithelial 
cell lipoapoptosis? In the present study we used the normal immortalized cholangiocyte cell 
line, H69, and cholangiocarcinoma-derived cell lines, KMCH, Mz-ChA-1, HuCCT, and 
BDEneu. H69 cells have been shown to share some characteristics with human primary 
cholangiocytes. H69 cells can produce primary cilia from the apical plasma membrane 
during in vitro culture conditions.17 In addition, H69 cells contain Cl-/HCO3- anion 
exchanger 2 (AE2) mRNA and protein and were shown to have AE2-mediated 
hydrocholeretic function similar to human cholangiocytes in 3D cultures.18 Proteomic 
studies from H69 cells have revealed the expression of Annexin A2, a Ca2+- and acidic 
phospholipid-binding protein and a marker for normal human cholangiocytes.19 This 
proteomic study also identified the expression of AE2 and several markers of cholangiocytes 
in H69 cells.19 Furthermore, mRNA and protein levels of G-protein-coupled receptor 55 
were found to be similar in H69, Mz-ChA-1, HuCCT cells and human intrahepatic biliary 
epithelial cells.20 Both normal cholangiocytes and cholangiocarcinoma-derived cell lines 
used in this study were shown to express keratin 7, keratin 19, and gamma-glutamyl 
transpeptidase activity, similar to cholangiocytes in vivo and primary human 
cholangiocytes.21 Thus, the cell lines employed in the current study share phenotypic 
features with biliary epithelial cells and are a useful culture model of cholangiocytes, 
although we recognize that cultured cells may not fully recapitulate cholangiocyte 
physiology.
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Saturated FFAs, like PA and SA, have been shown to cause lipoapoptosis due to the 
activation of caspases in pancreatic β-cells,10 hepatocytes,4,9 and other cell types. 
Hepatocytes and cholangiocytes have a common precursor cell, termed the bipotential 
hepatic progenitor cell.22 In the present study we report lipotoxicity due to saturated FFAs in 
biliary epithelial cells. This is a caspase-dependent process, consistent with previous studies 
in other cell types. Treatment with a pan-caspase inhibitor protected against cholangiocyte 
lipoapoptosis caused by saturated FFAs. Biliary injury has been reported in a subset of 
patients with NAFLD compared to a population with similar steatosis.22 Our data suggest 
that in patients with metabolic syndrome, higher circulating FFAs may contribute to biliary 
tree damage. Further studies will be needed to determine if cholangiocyte lipoapoptosis 
contributes to the progression of disease from simple steatosis to NASH to liver fibrosis, at 
least in a subset of patients.
JNK is one of the major cellular stress signaling kinases that is activated during FFA-
induced apoptosis. In particular, hepatocyte lipoapoptosis is dependent on JNK activation.4,9 
However, we found that inhibition of JNK using a small molecule inhibitor did not prevent 
cholangiocyte lipoapoptosis, suggesting a mechanism of apoptosis beyond JNK activation. 
A recent study in pancreatic β-cells showed that FFA-induced JNK activation is not critical 
for apoptosis, but JNK activation was involved in mediating ER-stress signaling pathways.23 
Several studies have also demonstrated that p38-MAPK and ERK can also induce apoptosis 
in pancreatic β-cells,24,25 but the activation of p38-MAPK and ERK has been shown not to 
be critical for FFA-induced hepatocyte lipoapoptosis.4 ERK was described as a negative 
regulator of FoxO3 nuclear accumulation, and phosphorylation of FoxO3 by ERK was 
shown to increase its interaction with MDM-2, resulting in ubiquination and degradation of 
FoxO3.26 In the present study we observed a partial inhibition of cholangiocyte 
lipoapoptosis with an ERK-selective inhibitor, FR180204. However, FR180204 can also 
inhibit p38α at 30 μM, a dose similar to the present study.27 Inhibition of p38 by SB204580 
caused partial protection of cholangiocytes, thus it is still not clear whether FR180204 
treatment resulted in partial protection by way of inhibiting p38α. Further work is needed to 
elucidate this mechanism.
Our next focus was on FoxO3. FoxO3 has been shown to activate cell death pathways by 
inducing the expression of proapoptotic proteins such as PUMA, Bim, p27, and TRAIL.7,8 
FoxO3 can also be regulated by the Akt signaling pathway, protein phosphatases, and 
protein deacetylases (Sirt1).29,30 Phosphorylation and acetylation of FoxO3 has been shown 
to alter cell death pathways towards cell survival by promoting export of FoxO3 from the 
nucleus to the cytoplasm.29 On the other hand, deacetylation of FoxO3 by Sirt1 in the 
nucleus decreased the proapoptotic transcriptional program.30 In the present study, 
deacetylation and dephosphorylation of nuclear FoxO3 were observed at the early 
timepoints after PA treatment in KMCH cells. However, after 16 hours of PA treatment the 
levels of acetylated nuclear FoxO3 and phosphorylated nuclear FoxO3 were increased, 
despite reports that phosphorylation promotes nuclear export. We conclude that in PA-
treated cholangiocytes, phosphorylation of FoxO3 at Thr32 is not sufficient to cause nuclear 
export and FoxO3 inactivation. Previously, PA has been shown to decrease the expression of 
Sirt1 in pancreatic β-cells,10 and overexpression of Sirt1 protected against FFA-induced 
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pancreatic β-cell apoptosis.31 Consistently, acetylated FoxO1 has been shown to induce Bim 
expression and promote apoptosis.32
As noted, PUMA is important in lipoapoptosis, and is a downstream target of FoxO3.8 
Expression of PUMA was found to be up-regulated in human liver biopsies taken from 
NASH patients as compared to control subjects.9 In our experiments, PUMA expression was 
up-regulated by FFAs in cholangiocytes. Our time-course of PUMA expression revealed a 
rapid increase in PUMA protein that is sustained through 48 hours. Knockdown of PUMA 
demonstrated its critical role in FFA-induced cholangiocyte lipoapoptosis.
Furthermore, we measured cellular steatosis, i.e., accumulation of triglycerides in lipid 
droplets, which has been reported in many nonadipose tissues including pancreatic β-cells34 
and hepatocytes.4 In the liver, there is controversy over whether lipid droplets in hepatocytes 
treated with FFAs promote lipotoxicity or serve as a protective mechanism for detoxifying 
FFAs.34-37 In the present study, FFA treatment of cholangiocytes did not induce cellular 
steatosis. These results are consistent with the clinical observation of hepatocyte lipid 
accumulation without biliary cell steatosis in NAFLD.38-40 Together, cholangiocytes 
undergo lipoapoptosis with FFA treatment, but unlike hepatocytes, cholangiocytes did not 
accumulate lipid droplets with FFA treatment.
In conclusion, our study shows that saturated FFAs induced cholangiocyte lipoapoptosis by 
way of caspase activation, nuclear translocation of FoxO3, and proapoptotic PUMA 
expression. Posttranslational modifications of FoxO3 may be involved in cholangiocyte 
lipoapoptosis. Further studies are required to elucidate the contribution of cholangiocyte 
lipoapoptosis to NAFLD or NASH in patients with metabolic syndrome.
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Fig. 1. 
FFAs induce cholangiocyte lipoapoptosis. (A) H69 cells were treated with 400, 600, or 800 
μM palmitate (PA), stearate (SA), or oleate (OA) for 24 hours. Apoptotic nuclei were 
counted and expressed as a percent of total nuclei (left panel). H69 cells were treated in 
parallel as above for 24 hours, followed by quantitation of caspase 3/7 activity (right panel), 
and results are expressed as fold-change over isopropanol-treated cells (Veh). The same 
conditions were employed to assess apoptotic nuclei and caspase 3/7 activity in KMCH cells 
(B), Mz-ChA-1 cells (C), and HuCCT cells (D). Each value represents the mean ± SEM of 
separate experiments (n = 6). *P < 0.001, compared to vehicle-treated cells. #P < 0.05 
compared to vehicle-treated cells.
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Fig. 2. 
Caspase-dependent cholangiocyte lipoapoptosis. (A) H69 cells were treated for 24 hours 
with 800μM palmitate (PA) or stearate (SA), and 50 μM caspase inhibitor, Z-VAD-fmk 
(ZVAD), or dimethyl sulfoxide (DMSO) as a control for the measurement of apoptotic 
nuclei. Apoptotic nuclei were counted and expressed as a percent of total nuclei, at least 100 
cells per replicate were counted (left panel). H69 cells were treated in parallel as above for 
24 hours, followed by quantitation of caspase 3/7 activity (right panel). Results are 
expressed as fold change of caspase 3/7 activity compared to vehicle treatment (Veh). The 
same conditions were employed to apoptotic nuclei and caspase 3/7 activity in KMCH cells 
(B), Mz-ChA-1 cells (C), and HuCCT cells (D). (E) BDEneu cells were treated with 600 μM 
palmitate (PA) or PA plus 50 μM caspase inhibitor, Z-VAD-fmk (ZVAD) for 24 hours, 
followed by quantitation of apoptotic nuclei (left panel) and caspase 3/7 activity (right 
panel) as above. Each value represents mean ± SEM of separate experiments (n = 6). *P < 
0.001, compared to vehicle, #P < 0.001, compared to 800 μM PA- or SA-treated cells.
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Fig. 3. 
FFAs induced p38-MAPK, ERK1/2, and JNK activation. (A) Cell lysates were prepared 
from KMCH cells treated with either 800 μM palmitate (PA) or vehicle (V) for different 
timepoints as indicated. Immunoblot analysis was performed for phospho p38-MAPK (P-
p38), phospho-ERK (P-ERK), and phospho-JNK (P-JNK), and compared with total p38-
MAPK (T-p38), total ERK (T-ERK), and total JNK (T-JNK), respectively. (B) Mz-ChA-1 
cells were treated with either 800 μM PA (PA) or vehicle (V) at different timepoints. 
Immunoblot analysis was performed in Mz-ChA-1 cells for phosphorylated proteins and 
compared with total p38, ERK, and JNK, respectively. (C) Cell lysates were prepared from 
H69, Mz-ChA-1, KMCH, HuCCT, and BDEneu cells to show the expression levels of T-
p38, T-ERK, T-JNK, FoxO3, PUMA, and actin. The images shown here are representative 
images. (D) H69, KMCH, Mz-ChA-1, HuCCT, and BDEneu cells were treated with vehicle 
(Veh) or 800 μM palmitate (PA), with or without 20 μM SB204580 (p38-MAPK inhibitor) 
for 24 hours, followed by caspase 3/7 activity and the results are expressed as fold change 
compared with vehicle-treated cells. (E) H69, KMCH, Mz-ChA-1, HuCCT, and BDEneu 
cells were treated with vehicle (Veh) or 800 μM palmitate (PA), with or without 30 μM 
FR180204 (selective ERK1/2 inhibitor) for 24 hours, followed by caspase 3/7 activity. (F) 
KMCH cells were treated with vehicle (Veh) or 800 μM palmitate (PA), with or without 50 
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μM SP600125 for 24 hours, followed by quantitation of apoptotic nuclei. Apoptotic nuclei 
were counted and expressed as a percent of total nuclei. (G) KMCH and Mz-ChA-1 cells 
were treated with vehicle (Veh) or 800 μM palmitate (PA), with or without 50 μM 
SP600125 (JNK inhibitor) for 24 hours, followed by caspase 3/7 activity. Vehicle was 
isopropanol (Veh <1% final) and control for SB204580, FR180204, and SP600125 was 
DMSO (<1% final). Each value represents the mean ± SEM of separate experiments (n = 6). 
*P < 0.001, compared to vehicle treated cells and n.s., nonsignificant.
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Fig. 4. 
Palmitate induced FoxO3 nuclear localization. (A) Nuclear extracts were prepared from 
KMCH cells treated with either 800 μM palmitate (PA) or vehicle (Veh) for the indicated 
times. Immunoblot analysis was performed for FoxO3 and Lamin B was used as a loading 
control. Numbers below indicate the quantitation of relative band intensity, presented as the 
ratio of FoxO3 to Lamin B. (B) H69 and Mz-ChA-1 cells were treated with 800 μM 
palmitate (PA) or vehicle (V) for 16 hours. Nuclear extracts were analyzed for FoxO3, 
FoxO1, and Lamin B. (C) Nuclear extracts were prepared from KMCH, H69, and HuCCT 
cells treated with either vehicle (Veh), 800 μM stearate (SA), or 800 μM palmitate (PA) for 
16 hours. Immunoblot analysis was performed for FoxO3 and Lamin B. Numbers below 
indicate the quantitation of relative band intensity, presented as the ratio of FoxO3 to Lamin 
B. (D) Immunofluorescence analysis of FoxO3 nuclear localization after 16 hours of 800 
μM palmitate (PA) or vehicle treatment in Mz-ChA-1 cells and nuclei were counterstained 
with DAPI. (E) Quantified levels of nuclear FoxO3 after 16 hours of 800 μM palmitate (PA) 
or vehicle treatment in Mz-ChA-1 cells. Relative fluorescent intensity was quantified using 
ImageJ software. At least 30 cells per treatment were analyzed. *P< 0.001 compared to 
vehicle-treated cells, Student t test. (F) Immunoprecipitation of total FoxO3 from nuclear 
extracts of KMCH cells treated with palmitate (PA) or vehicle (V) for 6 hours. Immunoblot 
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analysis was performed for acetylated FoxO3, phospho-FoxO3, and total FoxO3. Heavy 
chain of the IP antibody is indicated as IgG. (G) Immunoprecipitation of total FoxO3 from 
nuclear extracts of HuCCT, and H69 cells treated with 800 lM palmitate (PA) or vehicle (V) 
for 16 hours. Immunoblot analysis was performed for acetylated FoxO3, phospho-FoxO3, 
and total FoxO3. The images shown here are representative images.
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Fig. 5. 
FoxO3 is critical for cholangiocyte lipoapoptosis. (A) H69 cells transduced with either 
control shRNA (GFP) or FoxO3 shRNA (#1 and #2). Immunoblot analysis of nuclear 
FoxO3 in H69 cells were performed. (B) Immunoblot analysis of FoxO3 in KMCH cells 
transduced with either control shRNA (GFP shRNA) or FoxO3 shRNA (#1). Lamin B was 
used as a loading control. (C) Control shRNA or FoxO3 shRNA transduced stable H69 cells 
were treated with either vehicle (Veh), 800 μM palmitate (PA), or 800 μM stearate (SA) for 
24 hours. Apoptotic nuclei were counted and expressed as a percent of total nuclei (left 
panel). H69 cells were treated in parallel as above for 24 hours, followed by quantitation of 
caspase 3/7 activity (right panel), and results are expressed as fold-change over isopropanol-
treated cells (Veh). The same conditions were employed to assess apoptotic nuclei and 
caspase 3/7 activity in KMCH cells (D). Each value represents the mean ± SEM of separate 
experiments (n = 6). *P < 0.001, compared to vehicle-treated cells and #P < 0.001, 
compared to PA- or SA-treated GFP shRNA control cells.
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Fig. 6. 
Palmitate increased PUMA protein expression in cholangiocytes. (A) KMCH cells were 
treated with 800 μM palmitate (PA) or vehicle (Veh). Cell lysates were collected at different 
timepoints after PA treatment, as indicated. Immunoblot analysis was performed for PUMA 
and actin. (B) H69, Mz-ChA-1, and HuCCT cells were treated with either 800 μM of 
stearate (SA), palmitate (PA), or vehicle isopropanol (Veh). Cell lysates were prepared after 
16 hours of SA or PA treatment for the immunoblot analysis of PUMA and actin was used 
as a loading control. Numbers below indicate the quantitation of relative band intensity, 
presented as the ratio of PUMA to actin. (C) Immunoblot analysis of PUMA were 
performed in stable H69 cells transduced with either control shRNA (GFP) or PUMA 
shRNA (left panel). Control shRNA or PUMA shRNA transduced H69 cells were treated 
with vehicle (Veh), 800 μM palmitate (PA), or 800 μM stearate (SA) for 24 hours, followed 
by quantitation of caspase 3/7 activity (right panel) and results are expressed as fold change. 
(D) Immunoblot analysis of PUMA in stable HuCCT cells transduced with control shRNA 
(GFP) or PUMA shRNA were performed (left panel). Control shRNA and PUMA shRNA 
stable HuCCT cells were treated with vehicle (Veh), 800 μM palmitate (PA), or 800 μM 
stearate (SA) for 24 hours, followed by quantitation of caspase 3/7 activity (right panel). 
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Each value represents the mean ± SEM of separate experiments (n = 6). *P < 0.001, 
compared to vehicle-treated cells and #P < 0.001, compared to PA- or SA-treated cells.
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Fig. 7. 
Cholangiocytes do not develop steatosis with saturated FFA treatment. H69, Mz-ChA-1, 
KMCH cholangiocytes, or Huh7 hepatoma cells were treated with 600 μM palmitate (PA), 
stearate (SA), or oleate (OA) for 24 hours. Vehicle-treated cells were used as control (Veh). 
Red fluorescence was captured and images are displayed in grayscale. The images shown 
here are representative images and all micrographs were taken at the same magnification 
(scale bar = 25 μm).
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Fig. 8. 
Schematic representation of FFA-induced cholangiocyte lipoapoptosis. FFAs resulted in the 
activation of p38-MAPK (p38) and ERK by way of phosphorylation. FFAs also induced the 
nuclear accumulation of FoxO3, a forkhead family member. Posttranslational modification 
of FoxO3 can further promote its nuclear localization for the induction of lipoapoptosis and 
this in part can be regulated by the activation of p38 and ERK. Increased nuclear FoxO3 
levels potentially resulted in up-regulation of PUMA, a proapoptotic BH3-containing 
protein. Increased PUMA levels can trigger the activation caspases culminating in FFA-
induced cholangiocyte lipoapoptosis.
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